Jonat W, Maass H
Universitäts-Frauenklinik, Hamburg-Eppendorf, Federal Republic of Germany.
J Steroid Biochem. 1987;27(1-3):499-502. doi: 10.1016/0022-4731(87)90346-3.
Adjuvant therapy of breast cancer is accepted as a useful method for reducing mortality in patients with histologically axillary involved lymph nodes. Polychemotherapy regimens and hormonal treatment procedures are used to reach this goal. Hormonal treatment seems to be useful especially in selected patients. This article deals with (a) new methods for selecting hormone-responsive tumors and patients, and (b) it will give a brief overview of major publications concerning adjuvant endocrine therapy and (c) will summarize the data from the Gynecological Adjuvant Breast Group (GABG) trials.
乳腺癌辅助治疗被认为是降低组织学检查腋窝淋巴结受累患者死亡率的有效方法。多化疗方案和激素治疗程序被用于实现这一目标。激素治疗似乎特别适用于特定患者。本文涉及（a）选择激素反应性肿瘤和患者的新方法，（b）将简要概述有关辅助内分泌治疗的主要出版物，以及（c）将总结妇科辅助乳腺癌组（GABG）试验的数据。
